Glenmark Pharmaceuticals to Transfer Consumer Care Business to Wholly Owned Subsidiary

Mumbai / 15 September 2025 – Glenmark Pharmaceuticals Limited has announced the transfer of its Consumer Care business to Glenmark Consumer Care Limited, a wholly owned subsidiary of the company. The move follows the earlier intimation dated August 14, 2025, and marks a strategic step toward streamlining its operations. A Business Transfer Agreement was executed on 15th September 2025, with the transaction expected to be completed on or before 31st December 2025, subject to customary conditions and regulatory approvals. This restructuring will allow Glenmark to create a dedicated platform for its Consumer Care operations, providing enhanced focus and agility in a fast-growing segment. The subsidiary structure is expected to enable better resource allocation, sharper brand management, and improved operational efficiency. Speaking on the development, Glenmark’s management highlighted that the transfer aligns with the company’s broader vision of strengthening its portfolio while driving growth in high-potential areas. By creating a separate entity, the Consumer Care business will be better positioned to address market trends, innovation opportunities, and consumer needs. Investors and stakeholders are advised to note that this transaction is part of Glenmark’s ongoing efforts to optimize its business structure while unlocking value for shareholders. The company will continue to operate under its existing framework until the transaction is completed, ensuring business continuity and smooth execution. ⚠ Disclaimer: For information only, not financial advice. Verify before acting. 👉 Follow me for more updates on markets and news.